Article No
AFC-KMRNLM-0.1
Application | FC |
Article No | AFC-KMRNLM-0.1 |
Biosite Brand | Biosite Flow |
Country Availability | all |
Clone | 2E5 |
Clone Type | monoclonal |
Concentration | 0.1 mg/ml |
Conjugation | PE |
Description | Anti-Hu CD253 PE |
Recommended Dilution | The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography. |
Supplier | Nordic Biosite |
Entrez Gene ID | 8743 |
Format | PE |
Immunogen | Recombinant soluble fragment (aa 95-281) of human TRAIL. |
Isotype | IgG1 |
Keywords | CD and Related Antigens (Human), Apoptosis (Human), Apoptosis |
Notes | Human CD253 / TRAIL (TNF-related apoptosis inducing ligand), also called Apo2, is a type II membrane protein from the TNF family. TRAIL is a cytotoxic protein which activates rapid apoptosis in tumor cells, but not in normal cells. TRAIL-induced apotosis, is achieved through binding to two dealth-signaling receptors, DR4 (CD261 / TRAIL-R1) and DR5 (CD262 / TRAIL-R2). |
Alias Names | TRAIL, Apo-2 ligand, Apo-2L, TNFSF10, APO2L, TNLG6A |
Previous Article No | AFC-5159-2, AFC-KMRNLM-0.1 |
Product Type | Antibodies Primary |
Protocol | Flow cytometry: Recommended dilution: 1-5 μg/ml. |
Purification | Purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. Unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography. |
Research area | Immunology |
Size | 0.1 mg |
Source / Host | mouse |
Species Reactivity | human |
Storage | Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze. |
Substrate / Buffer | Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide |
Technical Specifications | The antibody 2E5 reacts with an extracellular epitope within C-terminal half of TRAIL (APO-2L), a 21 kDa cytotoxic protein, activator of rapid apoptosis in tumor cells. TRAIL is mainly expressed in spleen, lung, prostate and also in many other tissues. |
UniProt Number | P50591 |
Product Page Updated | 2024-01-03T12:18:20.318Z |